
Opinion|Videos|January 2, 2025
Utilizing Safety Data When Prescribing Ruxolitinib Cream for Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD
The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline
2
Uncovering the Autoimmune Links & Systemic Impact of Chronic Spontaneous Urticaria
3
10 Skin Cancer Exam Tips
4
Dermatology Times Conferences & Meetings Calendar: September 2026
5








